Comparison of Cisplatin with Lipoplatin in Terms of Ototoxicity | Zendy

Efe Serinan | Zendy; Zekiye Altun | Zendy; Safiye Aktaş | Zendy; Emre Çeçen | Zendy; Nur Olgun | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Comparison of Cisplatin with Lipoplatin in Terms of Ototoxicity

Author(s) -

Efe Serinan,

Zekiye Altun,

Safiye Aktaş,

Emre Çeçen,

Nur Olgun

Publication year - 2018

Publication title -

the journal of international advanced otology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.518

H-Index - 13

eISSN - 2148-3817

pISSN - 1308-7649

DOI - 10.5152/iao.2018.4097

Subject(s) - ototoxicity , nephrotoxicity , cisplatin , neurotoxicity , organ of corti , medicine , hearing loss , cochlea , pharmacology , toxicity , chemotherapy , oncology , audiology

Cisplatin (CDDP) is an anti-neoplastic agent that has been used in treatments of both pediatric and adult cancers. It has many side effects, such as ototoxicity, nephrotoxicity, and neurotoxicity. Lipoplatin (LIPO) is a nanomolecule with 110 nm diameter and composed of lipids and CDDP. In this study, we aimed to compare the toxic effects of LIPO with CDDP in the cochlear cells with anti-tumoral doses determined in neuroblastoma cells.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research